Message :
Required fields
-- AFM24 preclinical in vivo data will be presented as a poster
-- Data on AFM13 in combination with adoptive NK cells will be presented
during a Major Symposium
Heidelberg, Germany, March 10, 2021 -- Affimed N.V. (Nasdaq: AFMD), a
clinical-stage immuno-oncology company committed to giving patients back
their innate ability to fight cancer, announced today that preclinical
anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) )
AFM24 have been accepted for e-poster presentation at the American
Association for Cancer Research (AACR) Virtual Annual Meeting I, being
held on April 10-15.
In addition, early data from a Phase 1 study evaluating AFM13 preloaded